BB 2983

Drug Profile

BB 2983

Alternative Names: GI 245402

Latest Information Update: 10 Nov 1997

Price : $50

At a glance

  • Originator British Biotech
  • Developer British Biotech; GlaxoSmithKline
  • Class Antirheumatics
  • Mechanism of Action Metalloprotease inhibitors; Peptide hydrolase inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Inflammatory bowel diseases; Rheumatic disorders

Most Recent Events

  • 10 Nov 1997 Discontinued-I for Inflammatory bowel disease in United Kingdom (PO)
  • 09 Oct 1997 Discontinued-I for Rheumatic disorders in United Kingdom (PO)
  • 17 Apr 1997 Phase-I clinical trials for Inflammatory bowel disease in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top